DMR procedure could improve glycemic control in type 2 diabetes patients….
Revita Duodenal Mucosal Resurfacing (DMR) procedure is the first procedure therapy that designed to change the inner surface of the duodenum as well as how the body absorbs and processes sugar.
The safety and effectiveness of the Revita DMR procedure was demonstrated by Manoel Galvao Neto, M.D, during an oral presentation at the 19th World Congress of International Federation for the Surgery of Obesity & Metabolism Disorders (IFSO 2014) on August 29. In a study, Dr. Neto and colleagues performed thermal ablation of the duodenal mucosa with the Revita System on 30 patients with uncontrolled diabetes and average HbA1c level of 9.2. After 3 months of receiving the DMR procedure, the HbA1c levels in 19 patients, who received DMR over several centimeters of their duodenum, dropped to 7.1. Meanwhile, patients who received DMR procedure over a shorter length of their duodenum did not experience significant improvement in their HbA1c levels.
According to Dr. Francesco Rubino, a professor and chair of Bariatric and Metabolic Surgery at King’s College London, the gastrointestinal tract plays an important role in the regulation of glucose metabolism, and bariatric surgery which involves a bypass of the duodenum is the only type of treatment that can lead to a complete and long-term remission of diabetes.
Fractyl Laboratories Inc., the company which developed the Revita DMR procedure, believes that their innovation can potentially delay the need for insulin therapy and benefit type 2 diabetes patients who are failing oral therapy. Dr. Rajagopalan, Fractyl CEO, said, "We are preparing to launch our multinational study by the end of the year and working towards our clinical development efforts in the U.S., which we expect to commence during 2016."
- Revita DMR procedure involves altering the inner surface of the duodenum and changes how the body absorbs and processes sugar.
- Positive clinical data was seen only in patients who received DMR over several centimeter of their duodenum.
- Revita DMR procedure has not been approved by FDA for treatment of T2DM.
Fractyl labs announce positive clinical data for first procedural therapy to treat type 2 diabetes. Fractyl. 4 Sep. 2014. Web. 14 Sep. 2014